Tenet Shatters Forecasts with High-Acuity Shift, Raises 2026 Outlook

DALLAS, TX – July 23, 2026

Tenet Healthcare Corporation (NYSE: THC) announced second-quarter 2026 results that significantly outpaced market expectations, prompting the company to raise its financial outlook for the full year. The Dallas-based healthcare giant reported a surge in profitability, attributing the success to a combination of disciplined cost management and a strategic pivot toward more complex, higher-value medical services.

"Strong same-store revenue growth and effective expense management drove our fundamental outperformance in the second quarter of 2026 compared to our original assumptions," said Saum Sutaria, M.D., Chairman and Chief Executive Officer of Tenet. "We are actively navigating current industry dynamics through excellent operational execution, investments in innovation, and a continued focus on higher acuity services to sustain growth, margins and significant free cash flow."

Navigating a Turbulent Healthcare Landscape

Tenet's financial performance painted a picture of robust health in a sector facing considerable strain. The company's net operating revenues for the quarter climbed 6.8% year-over-year to $5.628 billion, comfortably beating the Zacks Consensus Estimate of $5.44 billion. The bottom line was even more striking, with net income available to common shareholders soaring to $826 million, or $9.84 per diluted share, a dramatic increase from $288 million in the same period last year. On an adjusted basis, diluted earnings per share hit $6.12, crushing analyst consensus estimates of around $4.08 by a staggering 50%.

The outperformance comes as Tenet and its peers confront what Dr. Sutaria termed "current industry dynamics." A key challenge noted in the report was an "unfavorable payer mix due to lower exchange admissions." Broader industry analysis confirms that the 2026 expiration of enhanced premium tax credits for Affordable Care Act (ACA) health plans has led to millions of Americans losing coverage, weakening demand for elective surgeries and increasing the volume of uninsured patients. Major operators like HCA Healthcare and Universal Health Services have also flagged this trend as a significant headwind, with HCA projecting a potential drag of over $1 billion on its earnings.

Despite these sector-wide pressures, Tenet has effectively charted a course for growth. The company’s strategy hinges on offsetting lower-margin patient volumes by intensifying its focus on higher-acuity services—more complex and technologically advanced procedures that command higher reimbursement rates. This, coupled with what the company describes as "disciplined expense management," allowed it to expand profitability. The Hospital Operations segment, for instance, saw its Adjusted EBITDA margin widen to 18.0% from 15.6% a year ago, demonstrating the success of this strategic pivot.

The Ambulatory Powerhouse: USPI's Ascendant Role

A primary engine for Tenet’s impressive quarter was its Ambulatory Care segment, operated through its subsidiary United Surgical Partners International (USPI), the country's largest ambulatory platform. This segment delivered a 9.3% increase in net operating revenues to $1.388 billion and an 8.8% rise in Adjusted EBITDA to $542 million, all while maintaining a formidable 39.0% margin.

A deeper look at the numbers reveals a crucial technological and procedural shift. While same-facility system-wide surgical cases saw a slight dip of 1.2%, the net revenue generated per case surged by an impressive 6.3%. This powerful metric shows that USPI is successfully performing fewer, but significantly more valuable, procedures in its outpatient centers. The company attributed this directly to a focus on "higher acuity and favorable service mix."

This performance perfectly aligns with one of the most significant transformations in modern healthcare: the migration of complex surgeries from traditional inpatient hospitals to ambulatory surgery centers (ASCs). Fueled by innovations in minimally invasive surgical techniques, advanced anesthesia, and refined recovery protocols, procedures once deemed too complex for an outpatient setting are now becoming routine. This includes everything from total knee and hip replacements to complex spinal surgeries like laminectomies and even some robotic-assisted cancer treatments. This shift is heavily favored by payers and patients alike, as ASCs can offer the same high-quality procedure for 30-40% less than a hospital setting, along with greater convenience. As the market leader, USPI is capitalizing on this trend, turning a potential volume challenge into a high-margin strategic advantage.

A Confident Bet on Future Growth

Tenet’s leadership underscored its confidence in this strategy with a bold capital allocation plan. The company announced it had repurchased 5.68 million shares for $1.042 billion during the second quarter. More significantly, its Board of Directors authorized a new $2.0 billion increase to the share repurchase program, leaving a total of $2.13 billion available for future buybacks. Such an aggressive move signals a strong belief from management that its stock is undervalued and that its model will continue to generate substantial free cash flow.

This confidence is backed by a solid balance sheet, with a manageable net debt to Adjusted EBITDA ratio of 2.33x, and reflected in the company's substantially raised full-year 2026 outlook. Tenet now projects full-year Adjusted EBITDA to land between $4.830 billion and $5.030 billion, a massive increase from its prior guidance and well above analyst expectations. The forecast for adjusted diluted earnings per share was also lifted dramatically to a range of $20.30 to $21.69.

While a portion of the quarter's stellar results was boosted by a one-time $413 million revenue recognition from the early termination of a contract, the underlying operational strength is undeniable. The combination of strategic operational pivots toward higher-value care and bold capital management demonstrates a clear path forward, positioning Tenet to continue its strong performance in a rapidly evolving healthcare market.